European Commission approves Nucala treatment in three diseases
This marks the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA)
Read More
Tag: Nucala
CHMP recommends Nucala for three new indications
Positive opinions recommend approval for mAb in three additional eosinophil-driven diseases
Read More
NICE green light for GSK’s Nucala
Final guidance on the drug’s use to treat patients with severe eosinophilic asthma on the NHS has now been published
Read More
FDA set to review GSK’s Nucala for nasal polyps
Submission is based on data from the pivotal SYNAPSE study
Read More
New EU approval for GSK’s Zejula
Zejula is the first PARP inhibitor to be approved as monotherapy in the EU for patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status
Read More
GSK’s Nucala shows promise in nasal polyps
Nucala is the first anti-IL5 biologic to report positive Phase III results in patients with the condition says GSK
Read More
FDA OKs new administration options for GSK’s Nucala
The two new methods, autoinjector and a pre-filled safety syringe, are for patients or caregivers to administer once every four weeks.
Read More
NICE recommends Fasenra injection as asthma alternative
The National Institute for Health and Care Excellence (NICE) has recommended that a potentially life-changing treatment be available to people with a severe form of asthma on the NHS in England and Wales.
Read More
GSK files Nucala for wider paediatric use
GlaxoSmithKline is seeking to expand the use of its biologic Nucala in the US to include children aged six to 11 years with severe eosinophilic asthma.
Read More
Long-term data backs safety and efficacy of GSK’s Nucala
GlaxoSmithKline has reported long-term safety data showing a sustained reduction in severe asthma attacks and improved asthma control in patients taking its biologic Nucala.
Read More
US regulators reject GSK’s Nucala for COPD
GlaxoSmithKline’s bid to expand the use of its biologic Nucala in the US to include patients with coronary pulmonary obstructive disorder (COPD) has hit a significant setback.
Read More
GSK’s Nucala approved for younger asthma patients
GlaxoSmithKline’s Nucala has been approved for use in paediatric patients with severe eosinophilic asthma.
Read More
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
